Wortmannin
(Synonyms: 渥曼青霉素; SL-2052; KY-12420) 目录号 : GC12338渥曼青霉素是一种高效的 PI3 激酶特异性直接抑制剂,最初源自真菌 (1,2)。
Cas No.:19545-26-7
Sample solution is provided at 25 µL, 10mM.
Wortmannin is a highly potent direct inhibitor of PI3-kinase specificity originally derived from fungi (1,2). This inhibition is irreversible and non-competitive with an IC50 of 3 nM[2][3]. Wortmannin does not inhibit PI4 kinase, protein kinase C, or protein tyrosine kinases[4].
In Jurkat cell, at the concentrations of wortmannin commonly used to inhibit PI 3-kinases, PLK1 is also significantly inhibited[5]. In Swiss 3T3 cells, Wortmannin is a selective and reversible phosphatidylinositol 3-kinase inhibitor with an IC50 value of 1.9 nM[4].PI3-kinase is involved in the signal transduction pathway responsible for histamine secretion following stimulation of Fc epsilon RI and that wortmannin blocks these responses through direct interaction with the catalytic subunit of this enzyme[1].
Wortmannin treatment significantly slower the growth rate of murine C3H mammary tumor and human MCF-7 breast cancer xenograft. A dose of 1 mg/kg Wortmannin for 7 days decrease the tumor burdens in mice with established murine C3H mammary tumors by 54% relative to controls. Human MCF-7 breast cancer xenograft burdens are decreased by 97% relative to controls after 14 days of 1 mg/kg Wortmannin beginning 1 day after tumor implantation[6]. Wortmannin inhibits myosin light chain phosphorylation and contraction in rat aorta. As an inhibitor of MLCK, wortmannin can be used as a vasodilator and anti-inflammatory agent[7].
References:
[1]: Yano H, Nakanishi S, et,al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993 Dec 5;268(34):25846-56. PMID: 7503989.
[2]: Moon EK, Kim SH, et,al. Autophagy inhibitors as a potential antiamoebic treatment for Acanthamoeba keratitis. Antimicrob Agents Chemother. 2015 Jul;59(7):4020-5. doi: 10.1128/AAC.05165-14. Epub 2015 Apr 20. PMID: 25896709; PMCID: PMC4468686.
[3]: Liu Y, Jiang N, et,al. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007 Jan 26;282(4):2505-11. doi: 10.1074/jbc.M609603200. Epub 2006 Nov 29. PMID: 17135248.
[4]: Powis G, Bonjouklian R, et,al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994 May 1;54(9):2419-23. PMID: 8162590.
[5]: Liu Y, Shreder KR, et,al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol. 2005 Jan;12(1):99-107. doi: 10.1016/j.chembiol.2004.11.009. PMID: 15664519.
[6]: Lemke LE, Paine-Murrieta GD, et,al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-7. doi: 10.1007/s002800051123. PMID: 10550570.
[7]: Nakanishi S, Kakita S, et,al.Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem. 1992 Feb 5;267(4):2157-63. PMID: 1733924.
渥曼青霉素是一种高效的 PI3 激酶特异性直接抑制剂,最初源自真菌 (1,2)。这种抑制是不可逆的和非竞争性的,IC50 为 3 nM[2][3]。渥曼青霉素不抑制 PI4 激酶、蛋白激酶 C 或蛋白酪氨酸激酶[4]。
在 Jurkat 细胞中,在通常用于抑制 PI 3-激酶的渥曼青霉素浓度下, PLK1 也被显着抑制[5]。在 Swiss 3T3 细胞中,Wortmannin 是一种选择性和可逆的磷脂酰肌醇 3-激酶抑制剂,IC50 值为 1.9 nM[4]。PI3-激酶参与刺激后组胺分泌的信号转导通路Fc epsilon RI 和渥曼青霉素通过与该酶的催化亚基直接相互作用来阻断这些反应[1]。
渥曼青霉素治疗显着减缓了小鼠 C3H 乳腺肿瘤的生长速度和人类 MCF-7 乳腺癌异种移植物。相对于对照组,以 1 mg/kg 的剂量服用 Wortmannin 7 天可使患有小鼠 C3H 乳腺肿瘤的小鼠的肿瘤负荷降低 54%。在肿瘤植入后 1 天开始使用 1 mg/kg 渥曼青霉素 14 天后,人类 MCF-7 乳腺癌异种移植物负荷相对于对照组降低了 97%[6]。 Wortmannin 抑制大鼠主动脉肌球蛋白轻链磷酸化和收缩。作为MLCK抑制剂,渥曼青霉素可作为血管扩张剂和抗炎剂使用[7]。
Kinase experiment [1]: | |
Preparation Method |
For studies of the kinetics of inhibition of PtdIns-3-kinase by wortmannin, bovine brain enzyme was incubated with 0 to 14 nM wortmannin with varying ATP concentrations from 2.5 to 20 μM. For studies of the time course of PtdIns-3-kinase inhibition, wortmannin 0 to 14 nM, enzyme, and PtdIns were incubated for various times at room temperature before adding [γ-32P]ATP to start the reaction. |
Reaction Conditions |
0-14 nM wortmannin |
Applications |
Kinetic analysis demonstrates that wortmannin is a noncompetitive, irreversible inhibitor of phosphatidylinositol-3-kinase, with inactivation being both time- and concentration-dependent. |
Cell experiment [2]: | |
Cell lines |
Jurkat cells |
Preparation Method |
Jurkat-soluble fractions were treated with AX7503 (50 nM) for 60 min with or without preincubation with various concentrations of wortmannin (0.25‿0 nM) or LY294002 (10‿0,000 nM) for 10 min. |
Reaction Conditions |
Wortmannin (0.25‿0 nM) for 10 min |
Applications |
PLK1 activity was inhibited by wortmannin with an IC 50 value of 24 nM. |
Animal experiment [3]: | |
Animal models |
Scid mice |
Preparation Method |
Oral gavage; daily; in Scid mice; one group of eight mice is dosed with Wortmannin 1 mg/kg for all 14 days. The second group of eight mice is dosed with Wortmannin 1.5 mg/kg for the first 5 days and the dose is decreased to 1 mg/kg for the remaining treatment period. |
Dosage form |
1 mg/kg for 14 days; 1.5 mg/kg for 5 days + 1.0 mg/kg for 9 days. |
Applications |
Wortmannin treatment significantly slower the growth rate of murine C3H mammary tumor and human MCF-7 breast cancer xenograft. A dose of 1 mg/kg Wortmannin for 7 days decrease the tumor burdens in mice with established murine C3H mammary tumors by 54% relative to controls. Human MCF-7 breast cancer xenograft burdens are decreased by 97% relative to controls after 14 days of 1 mg/kg Wortmannin beginning 1 day after tumor implantation. |
References: [1]. Powis G, Bonjouklian R, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994 May 1;54(9):2419-23. PMID: 8162590. [2]. Liu Y, Shreder KR, et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol. 2005 Jan;12(1):99-107. doi: 10.1016/j.chembiol.2004.11.009. PMID: 15664519. [3]. Lemke LE, Paine-Murrieta GD, et al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-7. doi: 10.1007/s002800051123. PMID: 10550570. |
Cas No. | 19545-26-7 | SDF | |
别名 | 渥曼青霉素; SL-2052; KY-12420 | ||
化学名 | (1S,6bR,9aS,11R,11bR)-1-(methoxymethyl)-9a,11b-dimethyl-3,6,9-trioxo-3,6,6b,7,8,9,9a,10,11,11b-decahydro-1H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate | ||
Canonical SMILES | O=C1[C@](C([H])([H])[C@@]2([H])OC(C([H])([H])[H])=O)(C([H])([H])[H])[C@](C([H])([H])C1([H])[H])([H])C(C3=O)=C2[C@]4(C([H])([H])[H])C5=C3OC([H])=C5C(O[C@]4([H])C([H])([H])OC([H])([H])[H])=O | ||
分子式 | C23H24O8 | 分子量 | 428.43 |
溶解度 | ≥ 21.42mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3341 mL | 11.6705 mL | 23.341 mL |
5 mM | 0.4668 mL | 2.3341 mL | 4.6682 mL |
10 mM | 0.2334 mL | 1.1671 mL | 2.3341 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Megakaryopoiesis of CD34+CD90+ HSCs also required the activation of the PI3K- HSCB signaling axis. (E) Western blotting analyses demonstrated that both knocking down HSCB and wortmannin treatment could increase the protein level of TACC3 while reduce FOG1 nuclear translocation.
After the FBS deprivation treatment, K562 cells were incubated for 48 hours with 300 nM ruxolitinib, 200 nM wortmannin (GlpBio), 2 μM lonafarnib dissolved in dimethylsulfoxide (DMSO) and 10 μM MG132 dissolved.
Elife 13 (2024): RP95815. PMID: 38757931 -
Related Biological Data
Isolation and evaluation of properties of M2-EVs in vitro.(E)Representative images of M2-EVs uptake in PMφ stained with FITC Phalloidin(Green) and DAPI(Blue).Cells were pre-treated with DMSO, Baf-A1, Cyto D or Wtmn(Wortmannin) for 15 min,and the incubated PKH26-labeled M2-EVs (Red) for 4 h.
To determine the cellular uptake mechanism of M2-EVs,cells were pretreated with inhibitors including Bafilomycin A1(10nM),Cytochalasin D(0.5μM),and Wortmannin(0.5μM,Glpbio) for 30 min,and then incubated with PKH26-labeled EVs.
J Control Release 349 (2022): 118-132. PMID: 35792186